title: Comparative study of prophylactic oral ganciclovir and valacyclovir in high-risk kidney transplant recipients.
abstract: BACKGROUND
  Cytomegalovirus (CMV) is a major pathogen in renal transplant patients causing significant post-transplant morbidity and mortality. Prophylactic antiviral therapy, currently implemented in most kidney transplant centres, has significantly reduced the incidence of CMV infection after transplantation. Oral ganciclovir has been shown to be an effective prophylactic agent in preventing CMV disease and infection with a demonstrated superior efficacy over oral acyclovir. Valacyclovir, a prodrug of acyclovir with a higher level of bioavailability than acyclovir, has also been shown to be effective in preventing CMV disease when given as prophylactic treatment.
  
  
  METHODS
  In a retrospective analysis of 150 renal transplant recipients in our centre, we compared the efficacy of oral ganciclovir with valacyclovir in preventing CMV infection. Seventy-seven consecutive renal transplant recipients prophylactically treated with oral ganciclovir for 12 weeks after transplant were compared with 73 consecutive recipients treated with oral valacylovir for an equal length of time.
  
  
  RESULTS
  No difference was noted in the incidence of CMV infection between the two treatment groups (5.1 vs 5.4%) after a 6 month follow-up. Likewise, the incidence of acute rejection was similar in both groups (11.6 vs 6.8%). All cases of CMV infection occurred in high-risk patients (donor positive/recipient negative).
  
  
  CONCLUSIONS
  The prophylactic use of oral valacylovir is as effective as oral ganciclovir in reducing CMV infection and disease after kidney transplantation.
authors.affiliation: Division of Renal Diseases, Department of Medicine, Rhode Island Hospital, Brown University School of Medicine, Providence, RI, USA.
authors.forename: Angelito
authors.initials: A
authors.lastname: Yango
authors.forename: Paul
authors.initials: P
authors.lastname: Morrissey
authors.forename: Abdurahman
authors.initials: A
authors.lastname: Zanabli
authors.forename: James
authors.initials: J
authors.lastname: Beaulieu
authors.forename: Douglas
authors.initials: D
authors.lastname: Shemin
authors.forename: Lance
authors.initials: L
authors.lastname: Dworkin
authors.forename: Anthony
authors.initials: A
authors.lastname: Monaco
authors.forename: Reginald
authors.initials: R
authors.lastname: Gohh
mesh_terms: D000212:Acyclovir / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D000284:Administration, Oral; D000328:Adult; D003586:Cytomegalovirus Infections / Q000517:prevention & control*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D015774:Ganciclovir / Q000008:administration & dosage*; D006084:Graft Rejection; D006085:Graft Survival; D006801:Humans; D007676:Kidney Failure, Chronic / Q000276:immunology / Q000601:surgery; D016030:Kidney Transplantation / Q000009:adverse effects* / Q000379:methods; D008297:Male; D008875:Middle Aged; D009894:Opportunistic Infections / Q000517:prevention & control*; D011300:Preoperative Care; D011336:Probability; D012189:Retrospective Studies; D018570:Risk Assessment; D016896:Treatment Outcome; D000077483:Valacyclovir; D014633:Valine / Q000008:administration & dosage* / Q000031:analogs & derivatives*
chemical_list: D014633:Valine; D000077483:Valacyclovir; D015774:Ganciclovir; D000212:Acyclovir